Artifact GuideEU

EU MDR Clinical Evidence

Clinical evidence under Regulation (EU) 2017/745 is the clinical data and clinical evaluation result that allows a qualified assessment that a device is safe and achieves its intended clinical benefit when used as intended.

Use this page to structure the clinical evaluation file, equivalence rationale, clinical investigation decision, PMCF plan, GSPR linkage, and notified-body review package.

Back to main artifactReview sources
Author
Sorena AI
Published
May 9, 2026
Updated
May 9, 2026
Sections
5

Structured answer sets in this page tree.

Primary sources
4

Cited legal and guidance references.

Publication metadata
Sorena AI
Published May 9, 2026
Updated May 9, 2026
Overview

EU MDR clinical evidence work should connect the device's intended purpose, claims, risk profile, clinical data, PMCF, and technical documentation. The useful output is not a generic evidence memo; it is a traceable clinical evaluation record that supports the relevant General Safety and Performance Requirements (GSPRs), explains any remaining uncertainty, and is ready for notified-body assessment where a notified body is involved.

Section 1

Build the clinical evaluation around the MDR evidence question

Start with Article 61 and Annex XIV: identify the GSPRs that need clinical data, specify the device's intended purpose and target groups, define measurable clinical benefits and safety endpoints, and justify the level of clinical evidence needed for the device's characteristics, classification, intended purpose, and risks.

The clinical evaluation should then show the route used to reach the conclusion: available clinical data for the device, clinical data for an equivalent device where equivalence is demonstrated, clinical data from similar devices where it informs state of the art or study design, and any new clinical investigation data needed to close evidence gaps.

  • Define the device version, Basic UDI-DI where relevant, intended users, patient population, indications, contraindications, claims, accessories, and configurations covered by the evaluation.
  • Map each clinical claim and relevant GSPR to the data source that supports it, including literature searches, clinical investigation reports, PMS and PMCF data, registries, user feedback, complaints, vigilance information, and risk-management outputs.
  • Include both favourable and unfavourable data, then explain how data quality, relevance, bias, follow-up, sample size, and transferability affect the clinical conclusion.
  • Document the clinical evaluation report as part of the technical documentation, together with the clinical evidence, non-clinical evidence, risk-management links, and any unresolved questions for PMCF.
Sources for this answer
Regulation (EU) 2017/745 on medical devices
Article 61 and Annex XIV ground the clinical evaluation process, the need to justify the level of clinical evidence, the GSPR link, and the technical-documentation linkage.
MDCG 2020-6 - Clinical evidence for legacy devices
MDCG guidance used for the meaning of sufficient clinical evidence, clinical-data quality and quantity, legacy-device evidence, GSPR support, and continuous clinical evaluation.
Section 2

Decide when clinical investigations or other clinical data are enough

For implantable devices and class III devices, the MDR starts from a clinical-investigation expectation unless a specific Article 61 route applies. The clinical evaluation report should identify the route taken and explain whether the available clinical data are sufficient or whether new or additional clinical data must be generated.

Where a clinical investigation is needed, Annex XV expects an investigation plan that is scientifically robust, aligned with the clinical evaluation plan, and designed to confirm or refute the manufacturer's claims on safety, performance, clinical benefits, and benefit-risk. The investigation report should critically evaluate all collected data, including negative findings.

  • For clinical investigation reliance, keep the approved clinical investigation plan, endpoint rationale, statistical justification, monitoring records, investigator access to technical and clinical data, training evidence, and final clinical investigation report.
  • For literature or other existing clinical data, keep the search protocol, search report, selection criteria, appraisal method, full references, excluded-data rationale, and analysis showing relevance to the device and intended purpose.
  • For any decision not to perform a clinical investigation, document the MDR basis, the sufficiency of clinical data, any common specification relied on, and how remaining questions are assigned to PMS or PMCF.
  • For Article 61(10) arguments based on non-clinical methods, keep the risk-management basis, the interaction-with-the-body analysis, intended clinical performance, manufacturer claims, and the technical-documentation justification; do not use that route for class III or implantable devices.
Sources for this answer
Regulation (EU) 2017/745 on medical devices
Article 61 and Annex XV support the clinical-investigation decision, exceptions, clinical investigation plan content, and clinical investigation report expectations.
MDCG 2020-6 - Clinical evidence for legacy devices
MDCG 2020-6 grounds how sufficient clinical data can support legacy-device conformity and when evidence gaps need new clinical data or PMCF follow-up.
Section 3

Use equivalence only when the MDR criteria and data access are documented

Equivalence is not a shortcut to avoid evidence. Annex XIV requires technical, biological, and clinical characteristics to be considered, and MDCG 2020-5 emphasizes that differences must be fully identified, assessed, and scientifically justified so they do not create clinically significant differences in safety or clinical performance.

For each presumed equivalent device, keep a separate equivalence table and do not assemble equivalence from different devices for different features. If the clinical evidence depends on another manufacturer's device, verify the access-to-data position before relying on the data; for implantable and class III devices, MDR Article 61(5) requires a contract allowing full access to the technical documentation on an ongoing basis.

  • Compare clinical characteristics: same clinical condition or purpose, similar severity and disease stage, same body site, similar population, same kind of user, and similar relevant critical performance for the expected clinical effect.
  • Compare technical characteristics: design, specifications, properties, deployment method, principles of operation, critical performance requirements, software algorithms, and other characteristics relevant to safety or performance.
  • Compare biological characteristics: materials or substances in contact with the same tissues or body fluids, duration of contact, release characteristics, processing effects, and biological-safety implications.
  • Document the data-access source, version or generation of the equivalent device, regulatory status, identified differences, scientific justification, and why the data remain relevant to the device under evaluation.
Sources for this answer
MDCG 2020-5 - Clinical Evaluation: Equivalence
MDCG equivalence guidance used for technical, biological, and clinical comparison criteria, the need for scientific justification, device-by-device equivalence, and access-to-data constraints.
Regulation (EU) 2017/745 on medical devices
Article 61 and Annex XIV ground the legal role of equivalence, the implantable and class III rules, and the requirement that clinical evidence support the GSPRs.
Section 4

Tie PMCF, benefit-risk, and technical documentation together

PMCF is a continuous process that updates the clinical evaluation after CE marking. The PMCF plan should state why each activity is needed, which residual clinical uncertainties it addresses, what data quality and quantity are expected, how bias and missing data will be controlled, and when data will be analysed and reported.

The PMCF evaluation report should feed back into the clinical evaluation report, the risk-management file, the benefit-risk conclusion, IFU and labelling decisions, SSCP where applicable, PMS outputs, and corrective or preventive action decisions.

  • Use PMCF to confirm safety and performance over the expected lifetime, monitor known side effects and contraindications, identify unknown side effects, analyse emerging risks, check continued benefit-risk acceptability, and detect systematic misuse or off-label use.
  • Reference the clinical evaluation report and risk-management file sections that PMCF will monitor; if no relevant section exists, state that explicitly and justify it.
  • Select PMCF methods that match the device risk and uncertainty: literature screening, user or patient surveys, registry analysis, real-world evidence, extended follow-up, PMCF studies, or new post-market clinical investigations.
  • Keep the PMCF plan, PMCF activity rationale, data-quality assumptions, endpoints, timelines, PMCF evaluation report, and resulting updates inside the technical documentation.
Sources for this answer
Regulation (EU) 2017/745 on medical devices
Annex XIV Part B grounds PMCF as a continuous process, the PMCF plan contents, the PMCF evaluation report, and the link to clinical evaluation, risk management, and technical documentation.
MDCG 2020-6 - Clinical evidence for legacy devices
MDCG 2020-6 supports lifecycle clinical evaluation and the expectation that clinical data continue to demonstrate safety, performance, and benefit-risk acceptability.
Recommended next step

Turn MDR clinical evidence into a review-ready file

Use Sorena to connect clinical claims, GSPR support, equivalence rationale, PMCF, risk management, and notified-body questions in one cited evidence workflow.

Research workflow
Open Research Copilot

Answer MDR clinical evidence and equivalence questions with cited outputs.

Explore next step
Talk to Sorena
Talk through MDR clinical evidence

Review your clinical evaluation structure, PMCF plan, GSPR mapping, and notified-body response model.

Explore next step
Section 5

Prepare for notified-body review of clinical evidence

Where a notified body reviews the device, expect scrutiny of the clinical evaluation as part of the technical documentation assessment and surveillance. The MDR requires notified bodies to examine clinical evaluation planning, literature methodology, clinical investigations, equivalence, PMS and PMCF, clinical evaluation reports, and justifications for not performing clinical investigations or PMCF.

For higher-risk devices subject to clinical evaluation consultation, the notified body's clinical evaluation assessment report can be reviewed by an expert panel. The package should therefore make the benefit-risk conclusion, consistency with intended purpose and medical indications, PMCF plan, and residual evidence gaps easy to follow.

  • Provide a reviewer-ready index from each clinical claim to its supporting clinical data, GSPR, risk-control record, IFU or SSCP statement, and PMCF follow-up item.
  • Flag any unresolved clinical uncertainty, non-conformity, limitation in equivalent-device data access, missing follow-up, or PMCF dependency before the notified body has to infer it.
  • Show how clinical evidence is reflected in the information supplied with the device, including warnings, contraindications, user training, intended purpose, claims, and SSCP where applicable.
  • Keep the notified-body questions, deficiency responses, clinical evaluation assessment report conclusions, PMCF milestones, certification conditions, and post-certification surveillance actions with the technical file.
Sources for this answer
Regulation (EU) 2017/745 on medical devices
Annex VII and Annex IX ground notified-body assessment of clinical evaluation, clinical evidence, PMCF, benefit-risk, CEAR conclusions, and expert-panel consultation for certain devices.
European Commission - notified bodies for medical devices
Commission overview used only for the role and designation context of notified bodies that assess conformity before certain devices are placed on the market.
Primary sources

References and citations

European Commission - notified bodies for medical devices
health.ec.europa.eu
Referenced sections
  • Commission overview used only for the role and designation context of notified bodies that assess conformity before certain devices are placed on the market.
"assess the conformity of certain products"
MDCG 2020-5 - Clinical Evaluation: Equivalence
health.ec.europa.eu
Referenced sections
  • MDCG equivalence guidance used for technical, biological, and clinical comparison criteria, the need for scientific justification, device-by-device equivalence, and access-to-data constraints.
"proper scientific justification"
MDCG 2020-6 - Clinical evidence for legacy devices
ec.europa.eu
Referenced sections
  • MDCG 2020-6 supports lifecycle clinical evaluation and the expectation that clinical data continue to demonstrate safety, performance, and benefit-risk acceptability.
"clinical evaluation is a process"
Regulation (EU) 2017/745 on medical devices
eur-lex.europa.eu
Referenced sections
  • Annex VII and Annex IX ground notified-body assessment of clinical evaluation, clinical evidence, PMCF, benefit-risk, CEAR conclusions, and expert-panel consultation for certain devices.
"review the clinical evidence presented"
Related guides

Explore more topics

Custom-made medical devices under the EU MDR | EU MDR FAQ
Concise EU MDR FAQ on custom-made device definition, mass-produced exclusions, Annex XIII statements, documentation, conformity assessment, PMS, vigilance, and records to retain.
EU MDR Annex II and III Technical Documentation
Build an MDR technical documentation index for Annex II device files and Annex III post-market surveillance evidence, including GSPR, risk, clinical, PMS, UDI, and EUDAMED records.
EU MDR Annex VIII Classification Guide
Classify EU MDR medical devices under Annex VIII using intended purpose, duration, invasiveness, active device and software rules, and conformity assessment impact.
EU MDR Annex XVI products without a medical purpose
source-linked EU MDR guide for Annex XVI products: listed product groups, common specifications, clinical evidence, notified-body route, UDI, EUDAMED, PMS, and vigilance evidence before launch.
EU MDR Applicability Test
Test whether a product, accessory, software function, or Annex XVI product falls under the EU Medical Device Regulation, and record the evidence for the next classification step.
EU MDR change assessment workflow
Assess EU MDR device, design, software, intended purpose, QMS, clinical, PMS, UDI, classification, and notified-body impacts before releasing a medical device change.
EU MDR Checklist for Medical Device Compliance
Practical EU MDR checklist covering qualification, classification, conformity assessment, technical documentation, GSPR, clinical evidence, UDI, EUDAMED, PMS, vigilance, QMS, and legacy transition evidence.
EU MDR classification workflow
A concrete EU MDR classification workflow for intended purpose, device or accessory qualification, Annex VIII rule selection, Rule 11 software review, class outcome, and notified body impact.
EU MDR Clinical Evaluation Overview
EU MDR clinical evaluation overview covering Article 61, Annex XIV, clinical data sources, equivalence, PMCF, CER evidence, notified body review, GSPR, and benefit-risk support.
EU MDR Clinical Evaluation Report Template
A source-linked EU MDR clinical evaluation report template covering intended purpose, GSPR linkage, clinical data appraisal, equivalence limits, PMCF, conclusions, and reviewer signoff.
EU MDR compliance obligations
EU MDR compliance guide for device qualification, classification, conformity assessment, QMS, technical documentation, UDI, EUDAMED, PMS, vigilance, and legacy transition controls.
EU MDR conformity route workflow
source-linked EU MDR workflow for classifying a device, choosing the conformity assessment route, preparing technical and QMS evidence, and reaching certificate, DoC, UDI, EUDAMED, and CE outputs.
EU MDR deadlines and compliance calendar
Grounded EU MDR calendar for application, legacy-device transition, UDI, EUDAMED, and recurring QMS, technical documentation, clinical, PMS, vigilance, certificate, and change reviews.
EU MDR Device Classification Guide
Classify an EU MDR medical device by intended purpose, Annex VIII duration, invasiveness, active-device and software rules, then document the conformity route impact.
EU MDR EUDAMED and UDI registration
source-linked MDR guide to Basic UDI-DI, UDI-DI, EUDAMED device registration, actor roles, labels, technical documentation, and UDI data governance.
EU MDR FAQ: qualification, evidence, UDI, and transition
Concise EU MDR FAQ covering device qualification, software classification, accessories, custom-made devices, clinical evidence, UDI, EUDAMED, notified bodies, significant changes, and legacy transition.
EU MDR Legacy Device Transition
source-linked EU MDR legacy device transition guide covering Regulation (EU) 2023/607 conditions, certificate validity, significant-change limits, surveillance, PMS, vigilance, QMS, and evidence records.
EU MDR notified body route selection
Choose an EU MDR conformity assessment route by device class, Article 52 option, notified body designation scope, QMS readiness, technical documentation, clinical evidence, and certificate evidence.
EU MDR penalties and enforcement risk
source-linked EU MDR penalties and enforcement-risk guide covering Article 113, Member State penalty rules, market restrictions, recalls, certificate consequences, and evidence.
EU MDR PMS and Vigilance Guide
EU MDR guide to post-market surveillance, PMCF updates, PMS reports, PSURs, serious incident reporting, FSCA/FSN handling, trend reporting, and evidence records.
EU MDR PMS and vigilance records
source-linked EU MDR guide to PMS plans, PMS reports, PSURs, PMCF updates, serious incident and FSCA reporting, trend reporting, and EUDAMED evidence handling.
EU MDR PMS Plan Template for Medical Devices
A source-linked EU MDR post-market surveillance plan template covering device scope, PMS data sources, PMCF linkage, vigilance, trend reporting, PMSR or PSUR outputs, roles, cadence, and evidence records.
EU MDR QMS and technical file evidence map
Map EU MDR Article 10 QMS duties to Annex II and Annex III technical documentation, PMS, vigilance, UDI records, and notified-body review evidence.
EU MDR QMS requirements under Article 10
EU MDR QMS guide for Article 10 manufacturer controls covering regulatory strategy, design, risk, clinical evaluation, PMS, vigilance, UDI, suppliers, CAPA, and conformity records.
EU MDR qualification and borderline products
EU MDR qualification guide for medical purpose claims, accessories, software, Annex XVI products, and borderline routes to classification and conformity assessment.
EU MDR qualification workflow
A concrete EU MDR workflow for deciding whether a product is a medical device, accessory, Annex XVI product, IVD interface, medicinal-product interface, or non-MDR product before classification and conformity assessment.
EU MDR requirements checklist
Concrete EU MDR requirements for medical-device scope, classification, GSPR, conformity assessment, technical documentation, QMS, clinical evidence, UDI, EUDAMED, PMS, vigilance, and economic-operator records.
EU MDR Rule 11 software classification
Classify MDR medical device software under Rule 11 using intended purpose, diagnosis or therapy decision impact, physiological monitoring, conformity route, clinical evidence, and software-change records.
EU MDR significant changes FAQ: legacy-device transition and notified-body review
FAQ on MDR significant changes for legacy devices, including intended-purpose, design, software, material, sterilisation, clinical, QMS, notified-body, and evidence impacts.
EU MDR Transition Timelines: practical guide
EU Medical Device Regulation guide to Transition Timelines with scope decisions, owner actions, evidence records, source-linked citations, and practical next steps.
EU MDR UDI and EUDAMED registration guide
EU MDR guide to Basic UDI-DI, UDI-DI, UDI carriers, EUDAMED actor and device registration, change impacts, and evidence governance.
EU MDR vigilance reporting workflow
Concrete EU MDR vigilance workflow for incident intake, serious incident assessment, FSCA and FSN handling, trend reporting, EUDAMED caveats, CAPA, PMS, clinical evaluation updates, and records.
How should Basic UDI-DI and UDI-DI be assigned under the EU MDR? | EU MDR FAQ
EU MDR FAQ explaining what Basic UDI-DI and UDI-DI identify, how they connect to UDI carriers, EUDAMED records, change triggers, and retained evidence.
MDR vs AI Act for medical-device software
Compare MDR software qualification, classification, clinical evidence, QMS, PMS, UDI, EUDAMED, and notified-body evidence boundaries against cautiously scoped AI Act overlap.
MDR vs GPSR: medical-device boundary checks
Compare MDR medical-device scope with general product-safety fallback questions for borderline, non-medical, and Annex XVI products.
MDR vs IVDR: medical devices and IVDs compared
Compare EU MDR and IVDR scope, classification, conformity routes, technical documentation, clinical or performance evidence, UDI, EUDAMED, PMS, and vigilance.
MDR vs Product Liability Directive evidence comparison
Compare EU MDR market-access evidence with Product Liability Directive exposure without treating compliance records as a liability outcome.
What should an EU MDR PMCF plan and report cover? | EU MDR FAQ
Under the EU MDR, PMCF is part of PMS and clinical evaluation. See what the plan, activities, report, updates, and retained evidence should cover.
What should manufacturers do when an EU MDR classification changes? | EU MDR FAQ
Concise EU MDR FAQ on classification changes, intended purpose, software, notified-body route impact, certificates, technical documentation, and retained evidence.
When can clinical equivalence be used under the EU MDR?
EU MDR FAQ on clinical equivalence, including technical, biological, and clinical characteristics, access to equivalent-device data, class III and implantable-device limits, clinical evaluation, PMCF, and retained evidence.
When do software or products make medical purpose claims under the EU MDR? | EU MDR FAQ
EU MDR FAQ on medical purpose claims, intended purpose evidence, software qualification, Annex XVI contrasts, and records to keep.
When is a PSUR required under the EU MDR and what should it contain? | EU MDR FAQ
EU MDR FAQ on PSUR scope, content, update cadence, PMS and PMCF links, notified-body handling, EUDAMED submission, and evidence to retain.
When is an accessory regulated under the EU MDR? | EU MDR FAQ
EU MDR FAQ on when an article is a medical device accessory, how intended purpose affects classification, and what evidence to keep.
When is software regulated as SaMD under the EU MDR? | EU MDR FAQ
Concise EU MDR FAQ on software qualification, intended medical purpose, Rule 11 classification, modules, clinical evidence, change assessment, UDI, and EUDAMED.
Which devices need an SSCP under the EU MDR and what should it include? | EU MDR FAQ
EU MDR FAQ on when an SSCP is required, who prepares, validates, uploads, and updates it, and what evidence should support the summary.
Which EUDAMED modules matter under the EU MDR? | EU MDR FAQ
EU MDR FAQ mapping EUDAMED modules to actor registration, UDI/device data, certificates, clinical investigations, vigilance/PMS, market surveillance, and practical records.